Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MLTX vs MAZE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MAZE Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–2 Matrix Metrics)

MAZE Overall Winner 6-Pillar Tally: MLTX 2 – 3 MAZE (1 Tie) Matrix Metrics: MLTX 2 – 6 MAZE

As of Nov 16, 2026, Maze Therapeutics, Inc. (MAZE) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas MAZE carries 34.8/100 (SELL) at $34.16 (8.5x Forward P/E, -820.8% operating margin).

  • Composite vs. Pillar Nuance: While MLTX currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. MAZE 34.8/100 SELL), MAZE captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-820.8% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although MAZE compares more favorably head-to-head, both MLTX (38.3/100 SELL) and MAZE (34.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile MAZE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MLTX vs MAZE
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82
MAZE NASDAQ Head-to-Head Winner
Maze Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$34.16
-0.5% 1D
Market Cap $2.0B
TTM Revenue $20M
Forward P/E 8.5x
Beta / 30D Vol 0.78β · 54% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 8.0 Fund 30.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.5% over 20 days), RSI 60
RSI-14: 59.6 · SMA20: $33.02 · SMA50: $28.84

6-Pillar Scorecard Institutional Category Breakdown (MLTX 2 – 3 MAZE)

Columns: Metric · MLTX · MAZE
1. Valuation Multiples MAZE
Forward P/E N/M 8.5x
Trailing P/E N/M 8.5x
PEG Ratio N/M N/M
EV / Revenue N/M 98.7x
2. Growth & Scale MAZE
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $20M
Market Cap $1.1B $2.0B
3. Profitability & Quality MAZE
Gross Margin N/A 100.0%
Operating Margin 0.0% -820.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -81.5% -37.5%
4. Balance Sheet & Cash Flow MLTX
Cash Generation (TTM) -$244M -$162M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $278M Net Cash $7.59 Book/Sh · -37.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 111.8% (7th %ile) 96.4% (3rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MLTX (2) vs MAZE (6)
Institutional Metric MLTX MAZE Criterion Row Edge
Market Capitalization
Scale
$1.1B $2.0B Larger Scale MAZE
Trailing P/E Ratio
Valuation
N/M 8.5x Lower Multiple MAZE
Forward P/E Ratio
Valuation
N/M 8.5x Lower Multiple MAZE
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -820.8% Higher Margin MLTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-81.5% -37.5% Higher ROE MAZE
52-Week Range Position
Momentum
17% ($9–$23) 38% ($22–$54) Stronger Trend MAZE
Beta / 30D Volatility
Risk Regime
1.61β · 90% Vol 0.78β · 54% Vol Lower Realized Risk MAZE
Unified Institutional Score
Composite Signal
38.3 / 100 (SELL) 34.8 / 100 (SELL) Higher Composite MLTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 98.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$244M ($278M Net Cash) -$162M EBITDA ($7.59 Book/Sh · -37.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon Tie
MLTX: +24.08% · MAZE: +24.08%
3M Horizon MAZE +44.75 pp
MLTX: -27.48% · MAZE: +17.27%
6M Horizon MAZE +67.35 pp
MLTX: -27.92% · MAZE: +39.43%
1Y Horizon MAZE +12.94 pp
MLTX: -5.65% · MAZE: +7.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MLTX vs MAZE. Trailing 12-month operating profitability (MLTX 0.0% vs MAZE -820.8%) and valuation multiples (MLTX N/M vs MAZE 8.5x Forward P/E) are benchmarked directly in Pillar 4 below.

MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M
MAZE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross Margin100.0%
Op. Margin-820.8%
ROE / Fwd P/E-37.5% · 8.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MAZE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 96.4%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MAZE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MAZE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.0B market capitalization and -820.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MLTX vs MAZE Key Questions & Quantitative Answers

As of Nov 16, 2026, Maze Therapeutics, Inc. (MAZE) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MLTX carries a Unified Composite Score of 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin), whereas MAZE carries 34.8/100 (SELL) at $34.16 (8.5x Forward P/E, -820.8% operating margin). Composite vs. Pillar Nuance: While MLTX currently prints a higher short-term Unified Composite Score (38.3/100 SELL vs. MAZE 34.8/100 SELL), MAZE captures the overall institutional head-to-head verdict (6–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-820.8% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although MAZE compares more favorably head-to-head, both MLTX (38.3/100 SELL) and MAZE (34.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MLTX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5); meanwhile MAZE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 59.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MAZE leads the Growth & Scale pillar: MLTX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MAZE at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $20M TTM revenue (100.0% gross margin, -820.8% operating margin). On trailing 12-month operating scale, MLTX generates N/A in USD-normalized revenue versus $20M for MAZE. In operating R&D and SG&A reinvestment, MLTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MAZE.

MAZE screens cheaper on headline valuation multiples. MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MAZE trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 98.7x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MLTX (-81.5% ROE) versus MAZE (-37.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk). By comparison, MAZE carries 96.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.78β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.